<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408730</url>
  </required_header>
  <id_info>
    <org_study_id>Sci-B-Vac-002</org_study_id>
    <secondary_id>2017-001820-22</secondary_id>
    <nct_id>NCT03408730</nct_id>
  </id_info>
  <brief_title>Lot-to-lot Consistency of Sci-B-Vac™ in Adults</brief_title>
  <official_title>A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VBI Vaccines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VBI Vaccines Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to verify that the manufacturing equivalence of&#xD;
      Sci-B-Vac™ is consistent and to compare the immunogenicity and safety of a three-dose regimen&#xD;
      of Sci-B-Vac™ to a three-dose regimen of Engerix-B® in adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2017</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Double-blind Randomized Controlled Trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)</measure>
    <time_frame>4 weeks after third vaccination (Study Day 196)</time_frame>
    <description>To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of [0.67, 1.5].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)</measure>
    <time_frame>4 weeks after third vaccination (Study Day 196)</time_frame>
    <description>The difference in proportions [SPR(Sci-B-Vac®)-SPR(Engerix-B®)] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was &gt; 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)</measure>
    <time_frame>Day of vaccine administration and six subsequent days</time_frame>
    <description>Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2838</enrollment>
  <condition>Hepatitis B Vaccines</condition>
  <arm_group>
    <arm_group_label>Sci-B-Vac Lot A Hep B Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sci-B-Vac Lot A Hepatitis B Vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sci-B-Vac Lot B Hep B Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sci-B-Vac Lot B Hepatitis B Vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sci-B-Vac Lot C Hep B Vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sci-B-Vac Lot C Hepatitis B Vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator: ENGERIX-B Hep B Vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hepatitis B Vaccination</intervention_name>
    <description>Hepatitis B Vaccination</description>
    <arm_group_label>Comparator: ENGERIX-B Hep B Vaccination</arm_group_label>
    <arm_group_label>Sci-B-Vac Lot A Hep B Vaccination</arm_group_label>
    <arm_group_label>Sci-B-Vac Lot B Hep B Vaccination</arm_group_label>
    <arm_group_label>Sci-B-Vac Lot C Hep B Vaccination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any gender&#xD;
&#xD;
          -  Age 18-45 years&#xD;
&#xD;
          -  Healthy, as determined by a physical examination and values of laboratory tests&#xD;
&#xD;
          -  If female, either is not of childbearing potential, defined as postmenopausal for at&#xD;
             least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy&#xD;
             or hysterectomy), is of childbearing potential and must agree to use an adequate birth&#xD;
             control method&#xD;
&#xD;
          -  Able and willing to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vaccination with any Hep B vaccine (HBV) (licensed or experimental)&#xD;
&#xD;
          -  Treatment by immunosuppressant within 30 days of enrollment&#xD;
&#xD;
          -  History of immunological function impairment&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Immunization with attenuated vaccines (e.g. MMR) within 4 weeks prior to enrollment&#xD;
&#xD;
          -  Immunization with inactivated vaccines (e.g. influenza) within 2 week prior to&#xD;
             enrolment&#xD;
&#xD;
          -  Has received blood products or immunoglobulin within 90 days of enrollment or is&#xD;
             likely to require blood products during the study period&#xD;
&#xD;
          -  Subject in another clinical trial with an investigational drug or a biologic within 30&#xD;
             days of enrollment&#xD;
&#xD;
          -  Has received granulocyte-macrophage colony stimulating factor (G/GM-CSF) or&#xD;
             erythropoietin (EPO) within 30 days of enrollment or likely to require GM-CSF or&#xD;
             erythropoietin during the study period&#xD;
&#xD;
          -  Any history of cancer requiring chemotherapy or radiation within 5 years of&#xD;
             randomization or current disease.&#xD;
&#xD;
          -  Any skin abnormality or tattoo that would limit post-vaccination injection site&#xD;
             assessment&#xD;
&#xD;
          -  History of allergic reactions or anaphylactic reaction to any vaccine component&#xD;
&#xD;
          -  Unwilling, or unable in the opinion of the investigator, to comply with study&#xD;
             requirements&#xD;
&#xD;
          -  Immediate family members of study center staff&#xD;
&#xD;
          -  Current or past hepatitis B infection or prior vaccination as evidenced by HBV markers&#xD;
&#xD;
          -  Known hepatitis C infection or positive Hepatitis C serology at screening, unless&#xD;
             treated and cured&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection or positive HIV serology at&#xD;
             screening&#xD;
&#xD;
          -  Renal impairment with Glomerular Filtration Rate (GFR) &lt;90 mL/min/ 1.73 m2 at&#xD;
             screening&#xD;
&#xD;
          -  BMI ≥ 35&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Diagnosis of Type 1 or Type 2 diabetes or HbA1C ≥ 6.5% at screening&#xD;
&#xD;
          -  Any laboratory test abnormality that would be considered of Grade 1 severity or above&#xD;
             as per FDA guidelines for grading clinical laboratory abnormalities and is considered&#xD;
             as clinically significant by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Diaz-Mitoma, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>VBI Vaccines</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accel Research Sites</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Arizona, LLC</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CareOne Research</name>
      <address>
        <city>North Hollywood</city>
        <state>California</state>
        <zip>91606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Altanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research (ACR)</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research, LLC</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research (ACR)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicore Research Inc</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manna Research Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tampere</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinishe Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. George's University Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <results_first_submitted>September 21, 2020</results_first_submitted>
  <results_first_submitted_qc>September 21, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 14, 2020</results_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B Vaccines</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03408730/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03408730/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Comparator: ENGERIX-B Hep B Vaccination</title>
          <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination&#xD;
Engerix-B® Hepatitis B Vaccination, 20ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="P2">
          <title>Sci-B-Vac Lot A Hep B Vaccination</title>
          <description>Sci-B-Vac Lot A Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="P3">
          <title>Sci-B-Vac Lot B Hep B Vaccination</title>
          <description>Sci-B-Vac Lot B Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="P4">
          <title>Sci-B-Vac Lot C Hep B Vaccination</title>
          <description>Sci-B-Vac Lot C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="712"/>
                <participants group_id="P2" count="711"/>
                <participants group_id="P3" count="709"/>
                <participants group_id="P4" count="706"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="643"/>
                <participants group_id="P2" count="636"/>
                <participants group_id="P3" count="637"/>
                <participants group_id="P4" count="625"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two subjects randomized to receive Sci-B-Vac®, one in the Lot B group and one in the Lot C group, discontinued the study before receiving any vaccinations. One of these subjects withdrew consent and the other was discontinued due to non-compliance. Data from these two subjects are not included in the Baseline Characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>Comparator: ENGERIX-B Hep B Vaccination</title>
          <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination&#xD;
Engerix-B® Hepatitis B Vaccination, 20ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="B2">
          <title>Sci-B-Vac Lot A Hep B Vaccination</title>
          <description>Sci-B-Vac Lot A Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="B3">
          <title>Sci-B-Vac Lot B Hep B Vaccination</title>
          <description>Sci-B-Vac Lot B Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="B4">
          <title>Sci-B-Vac Lot C Hep B Vaccination</title>
          <description>Sci-B-Vac Lot C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="712"/>
            <count group_id="B2" value="711"/>
            <count group_id="B3" value="708"/>
            <count group_id="B4" value="705"/>
            <count group_id="B5" value="2836"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="8.10"/>
                    <measurement group_id="B2" value="33.8" spread="7.96"/>
                    <measurement group_id="B3" value="32.9" spread="8.00"/>
                    <measurement group_id="B4" value="33.9" spread="7.91"/>
                    <measurement group_id="B5" value="33.5" spread="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="421"/>
                    <measurement group_id="B2" value="408"/>
                    <measurement group_id="B3" value="395"/>
                    <measurement group_id="B4" value="414"/>
                    <measurement group_id="B5" value="1638"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="291"/>
                    <measurement group_id="B2" value="303"/>
                    <measurement group_id="B3" value="313"/>
                    <measurement group_id="B4" value="291"/>
                    <measurement group_id="B5" value="1198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="61"/>
                    <measurement group_id="B5" value="269"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="636"/>
                    <measurement group_id="B2" value="643"/>
                    <measurement group_id="B3" value="638"/>
                    <measurement group_id="B4" value="643"/>
                    <measurement group_id="B5" value="2560"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="654"/>
                    <measurement group_id="B2" value="650"/>
                    <measurement group_id="B3" value="641"/>
                    <measurement group_id="B4" value="650"/>
                    <measurement group_id="B5" value="2595"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="186"/>
                    <measurement group_id="B4" value="185"/>
                    <measurement group_id="B5" value="750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="493"/>
                    <measurement group_id="B2" value="489"/>
                    <measurement group_id="B3" value="493"/>
                    <measurement group_id="B4" value="490"/>
                    <measurement group_id="B5" value="1965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="705"/>
                    <count group_id="B5" value="2836"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&gt;30 kg/m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="135"/>
                    <measurement group_id="B5" value="504"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&lt;=30 kg/ m^2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="595"/>
                    <measurement group_id="B2" value="576"/>
                    <measurement group_id="B3" value="591"/>
                    <measurement group_id="B4" value="570"/>
                    <measurement group_id="B5" value="2332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <population>The smoking status of one subject in group &quot;Sci-B-Vac Lot C Hep B Vaccination&quot; was not documented.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="712"/>
                    <count group_id="B2" value="711"/>
                    <count group_id="B3" value="708"/>
                    <count group_id="B4" value="704"/>
                    <count group_id="B5" value="2835"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Current smoker/ tobacco user</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="139"/>
                    <measurement group_id="B3" value="142"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="542"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Former smoker/ tobacco user</title>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="131"/>
                    <measurement group_id="B4" value="136"/>
                    <measurement group_id="B5" value="545"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nonsmoker/ non-tobacco user</title>
                  <measurement_list>
                    <measurement group_id="B1" value="435"/>
                    <measurement group_id="B2" value="435"/>
                    <measurement group_id="B3" value="435"/>
                    <measurement group_id="B4" value="443"/>
                    <measurement group_id="B5" value="1748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)</title>
        <description>To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of [0.67, 1.5].</description>
        <time_frame>4 weeks after third vaccination (Study Day 196)</time_frame>
        <population>Per Protocol Set 1 included all subjects in the full analysis set who received all 3 vaccinations, had an evaluable serum immunogenicity samples at baseline and at the time point of interest, were seronegative at baseline, and had no major protocol violations leading to exclusion</population>
        <group_list>
          <group group_id="O1">
            <title>Sci-B-Vac Lot A Hep B Vaccination</title>
            <description>Sci-B-Vac Lot A Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O2">
            <title>Sci-B-Vac Lot B Hep B Vaccination</title>
            <description>Sci-B-Vac Lot B Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O3">
            <title>Sci-B-Vac Lot C Hep B Vaccination</title>
            <description>Sci-B-Vac Lot C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) of Anti-HBs at Day 196 for Lot-to-Lot Consistency (Per Protocol Set 1)</title>
          <description>To demonstrate the manufacturing equivalence, in terms of immunogenicity, as measured by GMC of antibodies, of 3 independent consecutive lots of the Sci-B-Vac® 4 weeks after the third vaccination. Lot-to-lot manufacturing consistency of Sci-B-Vac® is demonstrated if the 95% CIs of the adjusted anti-HBs GMC ratios between lots are within the pre-specified range of [0.67, 1.5].</description>
          <population>Per Protocol Set 1 included all subjects in the full analysis set who received all 3 vaccinations, had an evaluable serum immunogenicity samples at baseline and at the time point of interest, were seronegative at baseline, and had no major protocol violations leading to exclusion</population>
          <units>mIU/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="611"/>
                <count group_id="O2" value="610"/>
                <count group_id="O3" value="619"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5883.93" spread="5.423"/>
                    <measurement group_id="O2" value="4824.06" spread="6.293"/>
                    <measurement group_id="O3" value="5505.98" spread="5.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)</title>
        <description>The difference in proportions [SPR(Sci-B-Vac®)-SPR(Engerix-B®)] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was &gt; 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®</description>
        <time_frame>4 weeks after third vaccination (Study Day 196)</time_frame>
        <population>Per Protocol Set 2 included all subjects in Per Protocol Set 1 excluding subjects who attended visits outside of windows including Visit 3/Day 168 (±28 days) and Visit 44/Day 196 (-7/+14 days)</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator: ENGERIX-B Hep B Vaccination</title>
            <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination&#xD;
Engerix-B® Hepatitis B Vaccination, 20ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O2">
            <title>Pooled Sci-B-Vac®</title>
            <description>Pooled Sci-B-Vac Lot A, B and C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate (SPR) of Anti-HBs at Day 196 for Sci-B-Vac® Compared to Day 196 for Engerix-B® (Per Protocol Set 2)</title>
          <description>The difference in proportions [SPR(Sci-B-Vac®)-SPR(Engerix-B®)] and two-sided 95% CIs were summarized. If the lower bound of the 95% CI was &gt; 5%, Sci-B-Vac® was to be declared non-inferior to Engerix-B®</description>
          <population>Per Protocol Set 2 included all subjects in Per Protocol Set 1 excluding subjects who attended visits outside of windows including Visit 3/Day 168 (±28 days) and Visit 44/Day 196 (-7/+14 days)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="592"/>
                <count group_id="O2" value="1753"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="561"/>
                    <measurement group_id="O2" value="1740"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)</title>
        <description>Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.</description>
        <time_frame>Day of vaccine administration and six subsequent days</time_frame>
        <population>Safety Set included all subjects in the All Enrolled Set who received at least 1 vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Comparator: ENGERIX-B Hep B Vaccination</title>
            <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination&#xD;
Engerix-B® Hepatitis B Vaccination, 20ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O2">
            <title>Sci-B-Vac Lot A Hep B Vaccination</title>
            <description>Sci-B-Vac Lot A Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O3">
            <title>Sci-B-Vac Lot B Hep B Vaccination</title>
            <description>Sci-B-Vac Lot B Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
          <group group_id="O4">
            <title>Sci-B-Vac Lot C Hep B Vaccination</title>
            <description>Sci-B-Vac Lot C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subject-reporting Solicited Local and Systemic Adverse Events (AEs)</title>
          <description>Analysis of local and systemic solicited adverse events with an interval of onset of Day 1 to Day 7 after any vaccination with either Sci-B-Vac® or Engerix-B®, in adults ≥18 years old.</description>
          <population>Safety Set included all subjects in the All Enrolled Set who received at least 1 vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="712"/>
                <count group_id="O2" value="711"/>
                <count group_id="O3" value="708"/>
                <count group_id="O4" value="705"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384"/>
                    <measurement group_id="O2" value="527"/>
                    <measurement group_id="O3" value="536"/>
                    <measurement group_id="O4" value="542"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="519"/>
                    <measurement group_id="O3" value="535"/>
                    <measurement group_id="O4" value="541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis/itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="105"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness/erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling/edema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea/vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="87"/>
                    <measurement group_id="O4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="268"/>
                    <measurement group_id="O2" value="255"/>
                    <measurement group_id="O3" value="275"/>
                    <measurement group_id="O4" value="281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284"/>
                    <measurement group_id="O2" value="266"/>
                    <measurement group_id="O3" value="296"/>
                    <measurement group_id="O4" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231"/>
                    <measurement group_id="O2" value="289"/>
                    <measurement group_id="O3" value="316"/>
                    <measurement group_id="O4" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>Number (%) of subject-reporting unsolicited adverse events (AEs) and serious adverse events (SAEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>Comparator: ENGERIX-B Hep B Vaccination</title>
          <description>Active Comparator: ENGERIX-B Hepatitis B Vaccination&#xD;
Engerix-B® Hepatitis B Vaccination, 20ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="E2">
          <title>Sci-B-Vac Lot A Hep B Vaccination</title>
          <description>Sci-B-Vac Lot A Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="E3">
          <title>Sci-B-Vac Lot B Hep B Vaccination</title>
          <description>Sci-B-Vac Lot B Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
        <group group_id="E4">
          <title>Sci-B-Vac Lot C Hep B Vaccination</title>
          <description>Sci-B-Vac Lot C Hepatitis B Vaccination&#xD;
Sci-B-Vac® Hepatitis B Vaccination, 10ug, intramuscular (IM) injection at Days 0, 28, and 168.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal arteriovenous malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="381" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="376" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="392" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="399" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="77" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="105" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="705"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="712"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="711"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="708"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="705"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vlad Popovic</name_or_title>
      <organization>VBI Vaccines, Inc.</organization>
      <phone>416-418-4713</phone>
      <email>vpopovic@vbivaccines.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

